Fibrogen is a biotechnology company focused on developing innovative therapies for serious diseases. Their primary research areas include kidney disease, liver disease, and hematologic disorders. The company aims to address unmet medical needs through its advanced drug development programs. One of Fibrogen's notable products is roxadustat, a medication designed to treat anemia associated with chronic kidney disease. Roxadustat works by stimulating the body's natural production of erythropoietin, a hormone that promotes red blood cell formation. This approach offers a new treatment option for patients who struggle with anemia.